{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:12:10Z","timestamp":1773227530939,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jval.2020.04.1838","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T08:41:30Z","timestamp":1599813690000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients"],"prefix":"10.1016","volume":"24","author":[{"given":"Renske M.T.","family":"ten Ham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merel","family":"van Nuland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick A.","family":"Vreman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens G.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke M.","family":"H\u00f6vels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.04.1838_bib1","series-title":"Clinical Pharmacology and Biopharmaceutics Review(s): Zytiga (Abiraterone Acetate)","year":"2010"},{"issue":"21","key":"10.1016\/j.jval.2020.04.1838_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2020.04.1838_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2020.04.1838_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12094-018-1921-5","article-title":"Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis","volume":"21","author":"Koninckx","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.jval.2020.04.1838_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","article-title":"Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer","volume":"4","author":"Pollard","year":"2017","journal-title":"Asian J Urol"},{"issue":"1","key":"10.1016\/j.jval.2020.04.1838_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41391-019-0161-2","article-title":"Cost-effectiveness analysis of abiraterone acetate versus docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong\u2019s perspective","volume":"23","author":"Chiang","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.jval.2020.04.1838_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40258-017-0350-x","article-title":"Dutch economic value of radium-223 in metastatic castration-resistant prostate cancer","volume":"16","author":"Peters","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2020.04.1838_bib8","first-page":"1","article-title":"Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer","volume":"16","author":"Aguiar","year":"2018","journal-title":"Heal Econ Manag"},{"key":"10.1016\/j.jval.2020.04.1838_bib9","unstructured":"van der Graaff M. Farmacotherapeutic Report Abirateron (Zytiga) bij gemetastaseerd castratieresistent prostaatcarcinoom mCRPC [in Dutch]. Vol. 1. Diemen, The Netherlands: 2011. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2012\/01\/23\/abirateron-zytiga-bij-gemetastaseerd-castratieresistent-prostaatcarcinoom-mcrpc. Accessed August 15, 2020."},{"issue":"3","key":"10.1016\/j.jval.2020.04.1838_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.12954\/PI.14054","article-title":"Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice","volume":"2","author":"Lojanapiwat","year":"2014","journal-title":"Prostate Int"},{"key":"10.1016\/j.jval.2020.04.1838_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2016.11.027","article-title":"Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients","volume":"72","author":"Carton","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jval.2020.04.1838_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40262-018-0683-0","article-title":"Therapeutic drug monitoring of\u00a0oral anti-hormonal drugs in oncology","volume":"58","author":"Groenland","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"14","key":"10.1016\/j.jval.2020.04.1838_bib13","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","article-title":"Prospective international randomized Phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer","volume":"36","author":"Szmulewitz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jval.2020.04.1838_bib14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/jcph.564","article-title":"Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer","volume":"55","author":"Chi","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jval.2020.04.1838_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2020.02.012","article-title":"Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme","volume":"130","author":"Groenland","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jval.2020.04.1838_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2020.04.1838_bib17","first-page":"296","article-title":"Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide","volume":"10","author":"Behl","year":"2017","journal-title":"Am Heal Drug Benefits"},{"issue":"15_suppl","key":"10.1016\/j.jval.2020.04.1838_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.3117","article-title":"Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: real-life data from a therapeutic drug monitoring program","volume":"37","author":"Groenland","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2020.04.1838_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"16","key":"10.1016\/j.jval.2020.04.1838_bib20","first-page":"1","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.jval.2020.04.1838_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jval.2020.04.1838_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2020.04.1838_bib24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CMAR.S148323","article-title":"Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study","volume":"9","author":"Restelli","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.jval.2020.04.1838_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.jval.2020.04.1838_bib26","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mds119","article-title":"Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?","volume":"23","author":"Mezynski","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jval.2020.04.1838_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies","volume":"68","author":"Al Nakouzi","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jval.2020.04.1838_bib28","first-page":"657","article-title":"Re: Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Taneja","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.04.1838_bib30","series-title":"Abirateron (Zytiga) bij gemetastaseerd castratieresistent prostaatcarcinoom mCRPC [in Dutch]","author":"Boer","year":"2011"},{"key":"10.1016\/j.jval.2020.04.1838_bib31","series-title":"DBC product-finder for tariffs","year":"2018"},{"issue":"11","key":"10.1016\/j.jval.2020.04.1838_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1371\/journal.pone.0187477","article-title":"Update of the Dutch manual for costing in economic evaluations","volume":"12","author":"Kanters","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2020.04.1838_bib33","volume":"3","author":"Drummond","year":"2005"},{"issue":"May","key":"10.1016\/j.jval.2020.04.1838_bib35","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.ejim.2017.05.015","article-title":"Incremental cost-effectiveness ratio and net monetary benefit: current use in pharmacoeconomics and future perspectives","volume":"43","author":"Trippoli","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.jval.2020.04.1838_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5001\/omj.2011.21","article-title":"Food-drug interactions","volume":"26","author":"Bushra","year":"2011","journal-title":"Oman Med J"},{"issue":"4","key":"10.1016\/j.jval.2020.04.1838_bib38","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1200\/JOP.2013.001183","article-title":"Oral chemotherapy food and drug interactions: a comprehensive review of the literature","volume":"10","author":"Segal","year":"2014","journal-title":"J\u00a0Oncol Pract"},{"issue":"1","key":"10.1016\/j.jval.2020.04.1838_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","article-title":"Geometric method for measuring body surface area: A height weight formula validated in infants, children and adults","volume":"93","author":"Haycock","year":"1978","journal-title":"J Pediatr"},{"issue":"July","key":"10.1016\/j.jval.2020.04.1838_bib40","first-page":"1","article-title":"Assessment report Zytiga (abiraterone acetate)","volume":"44","year":"2017","journal-title":"Eur Med Agency"},{"key":"10.1016\/j.jval.2020.04.1838_bib41","unstructured":"Dutch National Health Institute (Zorginstituut Nederland). Drug costs in the Netherlands [Dutch]. https:\/\/www.medicijnkosten.nl\/. Published 2018. Accessed July 1, 2019."},{"issue":"5","key":"10.1016\/j.jval.2020.04.1838_bib42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3111\/13696998.2012.681718","article-title":"Healthcare resource use in advanced prostate cancer patients treated with docetaxel","volume":"15","author":"Mehra","year":"2012","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.jval.2020.04.1838_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2217\/cer-2017-0026","article-title":"Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands","volume":"6","author":"Ter Heine","year":"2017","journal-title":"J Comp Eff Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520322117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520322117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:03Z","timestamp":1761096123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520322117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1098301520322117"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.04.1838","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.04.1838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}